Cancer Research

Newborns with the common virus in the herpes family known as congenital cytomegalovirus have an increased risk of developing acute lymphocytic leukemia, according to a new analysis. The authors say the risk is even greater in Hispanic children, who are already at the highest risk for developing ALL.
Women taking tamoxifen for breast cancer were less likely to continue taking the drug if they suffered nausea and vomiting - yet so were women given a placebo who experienced the same symptoms. This is evidence that drugs are being unfairly blamed for natural symptoms. 

It's a chemophobia culture. People embrace homeopathy, naturopathy and various alternative techniques because they aren't required to have elaborate disclosures of side effects like real medicines have. And there is a culture war against drug companies, so if symptoms occur it may be easy to blame Big Pharma or Big Generic.
Currently, prostate-specific antigen (PSA) and other biomarkers are used for diagnosing and monitoring prostate cancer. However, biomarkers to selectively identify patients with high risk of recurrence, those who might benefit from intervention, and those who can safely choose active surveillance, are lacking. A new study in The Journal of Molecular Diagnostics describes a biomarker, PITX2 DNA methylation, which is capable of distinguishing cancerous tissue from non-cancerous tissue and predicting the risk of cancer recurrence using only small amounts of tissue obtained from core needle biopsies.
There is no clear cut-off age to stop breast cancer screening, according to a new analysis which adds support for guidelines that encourage screening decisions based on individual patients and their health status. But which puts doctors, hospitals and insurance companies at risk in a defensive medicine environment where there are unlimited potential damages if an attorney gets a cancer patient in front of a jury.
How cancer can suddenly reappear months, or years after treatment is complete is an ongoing mystery in incology.

A new study finds dormant tumor cells might have become latent because they cannibalized—basically ate—the body’s own stem cells. The team had been working on teaching adult stem cells from bone marrow, called mesenchymal stem/stromal cells (MSCs), to fight cancer when they noticed that the MSCs were disappearing from the cell cultures. The team was working on teaching adult stem cells from bone marrow, called mesenchymal stem/stromal cells (MSCs), to fight cancer when they noticed that the MSCs were disappearing from the cell cultures.

A recent news post on an exciting breakthrough in prostate cancer, which appeared this month of November 2016, piqued my interest since the subject was close to the research I worked on myself as a postdoctoral researcher.

 

I worked on deciphering the types of genes that were altered in prostate cancer in the presence or absence of the androgen hormone. Of course, I was concerned with picking out a few relevant genes and working on them individually rather than deciphering the signaling pathway involved.

 

Ovarian cancer is the most lethal gynecological malignancy., the seventh most common cancer in women and the 18th most common cancer overall, with over 200,000 new cases worldwide each year.

One in six women (17 percent) diagnosed with breast cancer go to their doctor with a symptom other than a lump - the most commonly reported breast cancer symptom - according to data from 2009/10 National Audit of Cancer Diagnosis in Primary Care presented at the 2016 National Cancer Research Institute (NCRI) Cancer conference in Liverpool. There are more than 53,600 breast cancers diagnosed in the UK every year and 11,400 deaths from the disease annually.

Breast symptoms, other than a breast lump, that may be a sign of cancer (termed 'non-lump' in the study) include nipple abnormalities, breast pain, skin abnormalities, ulceration, shape abnormalities and an infected or inflamed breast.

Pancreatic cancer is one of the most lethal forms of cancer. Early detection is essential to improve prognoses. Working toward that goal, a collaboration of researchers in Japan has discovered proteins in the blood which improve the detection of pancreatic cancer. When used in combination with conventional pancreatic cancer biomarkers, it enables the diagnosis of early stage pancreatic cancer, which was previously thought to be difficult.

Tumours are an accumulation of cells that divide without control, accumulating hundreds of chromosomal alterations and mutations in their DNA. These alterations are triggered in part by a type of damage to the DNA known as replicative stress. To survive in the face of this chaos, tumour cells need the intervention of the damage response protein ATR, known for its role as guardian of genome integrity, to which they become addicted. After eight years of work, Oscar Fernández-Capetillo's team at the Spanish National Cancer Research Centre (CNIO) has discovered that blocking this protein has antitumour effects in several animal models of cancer, such as an aggressive type of acute myeloid leukaemia and Ewing sarcoma.